Who Should Receive HMG CoA Reductase Inhibitors?

ISSN： 0012-6667

Source： Drugs, Vol.62, Iss.12, 2002-01, pp. : 1707-1715

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects of HMG-CoA Reductase Inhibitors on Skeletal Muscle: Are all Statins the Same?

By Evans M. Rees A.

Drug Safety, Vol. 25, Iss. 9, 2002-01 ,pp. : 649-663

Adis International

Access to resources Recommend Favorite

HMG-CoA Reductase Inhibitors: Do They Have Potential in the Treatment of Polycystic Ovary Syndrome?

By Kodaman Pinar H.

Drugs, Vol. 68, Iss. 13, 2008-01 ,pp. : 1771-1785

Adis International

Access to resources Recommend Favorite

HMG-CoA Reductase Inhibitors in Osteoporosis: Do They Reduce the Risk of Fracture?

By Schlienger R.G. Meier C.R.

Drugs & Aging, Vol. 20, Iss. 5, 2003-01 ,pp. : 321-336

Adis International

Access to resources Recommend Favorite

Who should receive booster hepatitis B vaccinations?

Inpharma, Vol. 1, Iss. 1225, 2000-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Secondary Prevention of Coronary Heart Disease in Elderly Patients Following Myocardial Infarction: Are All HMG-CoA Reductase Inhibitors Alike?

By Maroo Bijesh P. Lavie Carl J. Milani Richard V.

Drugs & Aging, Vol. 25, Iss. 8, 2008-01 ,pp. : 649-664

Adis International

Access to resources Recommend Favorite